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Aim: The aim of this study was to evaluate toxicity and response to fractionated reirradiation
(FR)  of relapsed primary brain tumors in children.
Background: The treatment options for recurrent brain tumors in children previously irradi-
ated are limited. Reirradiation is performed with fear due to the cumulative late CNS toxicity
and the lack of a signiﬁcant chance of cure.
Materials and methods: Between 2008 and 2009, eight children with a median age of 14.5
years with a diagnosis of a recurrent brain tumor underwent reirradiation. Initially, all
patients were treated with surgery, chemotherapy and radiotherapy. The median time to
the  ﬁrst recurrence after the initial treatment was 19.5 months. Intervals between radio-
therapy courses were in the range of 5–51 mos. All retreatments were carried out with
3D  image-based conformal methods. The total prescription dose was 40 Gy in a fraction
of  5 × 2 Gy/week. The total cumulative dose ranged from 65 to 95 Gy (median: 75 Gy). The
median cumulative biologically effective dose was 144 Gy (range: 126–181 Gy).
Results: The median overall survival and progression free survival measured from the begin-
ning of reirradiation was 17.5 and 6.5 months, respectively. During the ﬁrst evaluation, four
patients showed a complete or partial response, two did not respond radiologically. Two
children were progressive at the time of reirradiation. Among children with progression
that occurred during the ﬁrst year after reirradiation, only two progressed in the treatment
area. The repeated irradiation was well tolerated by all patients. No late complications have
been  observed.
Conclusion: In the absence of other treatment possibilities, the fractionated reirradiationwith highly conformal three-dimensional planning could be a therapeutic choice in case of
recurrent brain tumors in children. The control of craniospinal dissemination remains to be
the  main problem.
© 2011 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.∗ Corresponding author. Tel.: +48 225709186; fax: +48 225709186.
E-mail address: marzanna.ch1@wp.pl (M. Chojnacka).
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doi:10.1016/j.rpor.2011.10.004z.o.o. All rights reserved.. Published by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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.reports of practical oncology an
.  Background
entral nervous system (CNS) tumors account for about 20%
f all childhood malignancies. Notwithstanding the advances
n the treatment of pediatric brain tumors, in particular
edulloblastoma, in most series 30–40% of patients develop
ecurrences which result in death due to tumor progression.1
The treatment options for recurrent brain tumors in
hildren previously irradiated are limited. Reoperation and
tandard dose salvage chemotherapy are used in majority
f these patients providing a palliative effect. Reirradiation
ithin the central nervous system may result in temporary
ocal control but is performed with fear due to cumulative late
NS toxicity and the lack of a signiﬁcant chance of cure. It may
e offered only to selected patients with lesions of limited size
ocalized in a “safe” area. This is particularly important in the
reatment of children. In the literature there are only few pub-
ications concerning this topic. New conformal radiotherapy
echniques allow reduction of the treatment volume thereby
paring normal tissue, which consequently decreases the risk
f the late toxicity.2–6 Additionally, radiobiological data sug-
est at least partial repair of CNS radiation damage after the
nitial course of radiotherapy. The magnitude of this recovery
epends on the total dose and fractionation regimen in the
rst course and the time elapsed between treatments. Despite
his fact, many  different reirradiation treatment schemes
re used with regard to total dose, size and number of
ractions.7,8
Due to the low repair capacity of the brain tissue, reﬂected
n the / ratio, which is estimated to be approximately 2 Gy,
he biologically effective dose (BED) rather than the “physi-
al” irradiation dose, should be considered in the analysis of
adiotherapy protocols.9 Our data were analyzed using this
umulative BED, which is the sum of the BED of the initial
rradiation course and the BED of the reirradiation course.
.  Aim
he aim of this study was to evaluate toxicity and response
o fractionated reirradiation (FR) of relapsed primary brain
umors in children.
.  Materials  and  methods
.1.  Patients
n the period from January 2008 to September 2009, eight
hildren (5 male, 3 female) with a median age of 14.5 years
range 9–18.5 years) with a diagnosis of a recurrent brain tumor
nderwent reirradiation at the Radiotherapy Department of
SCM Cancer Centre in Warsaw. Both the clinical data and
adiotherapy technical records were reviewed.
The primary histological diagnoses included: six medul-oblastoma (MB), one germ cell tumor (GCT) and one non-germ
ell tumor (NGCT). Five patients with medulloblastoma were
lassiﬁed as a high risk group, only one (pt. 2 in Table 1) as
tandard risk.
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Initially, all patients were treated with surgery, chemother-
apy and radiotherapy. The radiotherapy doses were to the
central nervous system, ranging from 25.05 to 35.07 Gy with
a posterior fossa tumor bed boost to a total dose of 55.11 Gy (6
pts. with MB), and to the ventricle system (VS) of 24 and 30.6 Gy
with a primary tumor region boost of up to 40 and 54 Gy (2 pts.
with GCT and NGCT).
All patients with recurrent tumors were evaluated with
contrast-enhanced cranial and spine MRI. A relapse was
deﬁned as the progression of neoplasm at the original site or
the occurrence of a new tumor elsewhere. The disease relapse
was located in the tumor bed only in 2 children. In the other
cases, it appeared as an isolated metastasis in the brain in 3
patients and as multifocal in the remaining 3. No patient had
dissemination in the spine. The median time to the ﬁrst evi-
dence of recurrence after the prior treatment was 19.5 months
(range: 2–47 mos).
3.2.  Retreatment
At the time of tumor recurrence, only one patient was
treated with surgery. Seven children received salvage
conventional chemotherapy including multidrug regimens
such as: ETIF (etoposide, uromitexan, ifosfamide), ICE
(ifosfamide, carboplatin, etoposide), Temodal + Irinotecan,
Vepesid + Ifosfamid/DTIC and PVB (cisplatin, vinblastine,
bleomycine). Reirradiation was given with the intent to
consolidate the effect of chemotherapy. Intervals between
radiotherapy courses were in the range of 5–51 months
(median: 39 months). Six patients with MB were reirradi-
ated for recurrent tumors only. In the two remaining cases,
the irradiated volume was larger. In the patient with NGCT,
a prophylactic irradiation of the spine was performed addi-
tionally. The patient with GCT was ﬁrst irradiated for the
whole brain due to the multifocal relapse. All reirradiated
volumes comprised previously irradiated areas. Retreatment
was carried out with 3D image-based conformal methods.
The gross tumor volume (GTV) was contoured by using the
option of fusion images of CT and diagnostic MRI  scans.
The GTV was deﬁned by contrast enhancing area on T2-
weighted MRI-images. The planning target volume (PTV)
consisted of the GTV with a 4 mm safety margin. Mean
PTV was 24.4 ccm (range: 4.8–60.5 ccm). Summary (initial and
retreatment) dose-volume histograms (DVHs) for non-target
brain were compared for various plans and beam orienta-
tions which minimized normal brain tissue irradiation were
selected. DVHs for organs at risk such as brain stem or visual
pathway were particularly evaluated because of the risk of life-
threatening complications. Our goal was to reduce the dose
Table 2 – Reirradiation doses in brain stem and optic pathway [
1 2 3 
Brain stem (Dav/Dmax) 37/75 887/3793 47/78 
Optic pathway (Dav) 11 42 13 
Dav, average dose; Dmax, maximum dose.diotherapy 1 7 ( 2 0 1 2 ) 32–37
in these structures. Doses from reirradiation are presented in
Table 2.
Two to six ﬁelds formed by a multileaf collimator were
applied. In treatment plans, the high dose homogeneity was
achieved: Dmax < 105% was obtained in all plans, Dmin > 93%
was received in 7 plans; in the other two, Dmin was lower
because of the vicinity to the brain stem.
FR was delivered using a linear accelerator with 4, 6 and
15 MV photons. The total prescription dose was 40 Gy in 2 Gy
daily fractions. The total cumulative dose (TDcum) ranged from
65 to 95 Gy (median: 75 Gy). The median cumulative BED was
144 Gy (range 126–181 Gy). All children completed the second
course of radiotherapy, except one girl. Neurological condition
of this girl worsened during reirradiation. The MRI  showed
disease progression in the brain and we ﬁnished the treatment
after dose of 28 Gy.
The kilovoltage cone-beam CT was performed before the
ﬁrst and second reirradiation fraction and once weekly there-
after. The correction of the isocenter position was done when
the offset results were >2 mm.  Salvage chemotherapy based
on various regimens was applied in all children after repeated
radiotherapy.
3.3.  Follow-up
During the follow-up, all patients were seen at regular
intervals. The ﬁrst neurological examination and MRI were
performed 1–3 months following reirradiation, then at 3–4
months intervals in the ﬁrst post-radiotherapy year, and at
5–6 month intervals thereafter.
Central nervous system toxicity was deﬁned as the devel-
opment of any new neurologic symptoms (with or without MRI
abnormalities) after radiotherapy that may be attributed to
this treatment. Toxicity was deﬁned as acute when occurring
within 3 months after treatment and chronic when occurring
after more  than 3 months. The Radiation Therapy Oncology
Group (RTOG) CNS toxicity criteria were used to assess the
toxicity of the treatment.
4. Results
The evaluation was completed with a median follow-up of
16 months (range 6–27 mos). No patient was lost during the
follow-up. The median overall survival (OS) and progression
free survival (PFS) measured from the beginning of reirradia-
tion was 17.5 and 6.5 months, respectively. Results are showed
in Table 1.
The radiological response was assessed in all patients. Dur-
ing the ﬁrst evaluation after the retreatment, four patients
cGy].
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howed a complete or partial response, two did not respond
adiologically. Two children were progressive at the time of
eirradiation. One of these patients died 5 months after the
nd of reirradiation due to the CNS dissemination. The second
hild who  died after 12 months was the patient with NGCT. He
ad the non-local intracranial progression. Six other patients
re still alive, one with complete remission, one with partial
emission and 4 with progression. Among children with pro-
ression that occurred during the ﬁrst year after reirradiation,
nly two progressed in the treatment area. In the other cases,
here was a spread in the brain (2), spine (1) or throughout the
NS (1) without progression in the irradiated ﬁeld.
The repeated irradiation was well tolerated by all patients.
o grade 3–5 acute toxicity was detected. Four children had
ild symptoms of radiotherapy toxicity (grade 1) not requir-
ng medication, the other four had headache and vomiting
hat required steroids in low doses and/or antiemetic treat-
ent (grade 2). No severe late complications of reirradiation
ave been observed. Children retained a satisfactory func-
ional status. 95% conﬁdence interval for the probability of late
omplications ranged from zero to 0.375 (0; 0.375).
.  Discussion
eirradiation used in the management of recurrent brain
umors in adults and children is a controversial issue. This
ethod may result in a temporary local tumor control but
arries the risk of a late central nervous system damage.
e  have not performed the reirradiation in children before
008 for fear of the occurrence of serious complications of
his treatment. Decision of how to carry out the retreat-
ent is a complex process. The tolerance dose of normal
rain tissue to a single course of radiotherapy is estimated
o be 50–60 Gy in 2 Gy daily fractions. Less is known about
he tolerance to the second course.7 There are no experi-
ental data available on reirradiation tolerance of the brain.
ut some clinical series suggest that the reirradiation of the
rain may be associated with a lower incidence of severe com-
lications then previously feared. The following factors are
aken into account when planning the retreatment: type of tis-
ue exposed to damage, fractionation regimen, interval from
revious irradiation, observable normal tissue changes result-
ng from previous irradiation and patient’s life expectancy.8
ther suggested risk factors for radiation necrosis include:
hemotherapy use, lower conformality index, shorter overall
reatment time, older age and diabetes mellitus.10
Although location does not inﬂuence the susceptibility to
adiation necrosis, necrosis is far more  likely to be symp-
omatic in certain areas, e.g. the corpus callosum and brain
tem.10 Therefore the location of PTV and its volume often
nﬂuence the choice of reirradiation technique.11 Our current
adiotherapy technique for retreatment utilizes multiple, non-
oplanar 3D conformal beam arrangements which minimize
he overlap with previously irradiated volumes, especially in
he brain stem. Earlier, some authors used the whole brain
rradiation or a simple technique with opposed ﬁelds. How-
ver, in their series a higher risk of toxicity was stated.7,12
In all our patients, we planned the reirradiation dose of
0 Gy in 2 Gy daily fractions. The argumentation for this doseiotherapy 1 7 ( 2 0 1 2 ) 32–37 35
level was two-fold. Firstly, several studies have demonstrated
no severe brain injury in patients treated with cumulative
doses of up to 100 Gy (2 Gy daily fractions; BED 200 Gy). Sec-
ondly, the dose of reirradiation course should be high enough
to obtain temporary local tumor control.7,9,13
In the overview of current clinical data on reirradiation
of patients with glioma, no cases of necrosis were found
when the normalized total cumulative dose (NTDcum) was
<100 Gy. The NTDcum was the most important factor with
regard to the development of radionecrosis. No effect was
noticed for the time interval between the initial and reirradi-
ation exposure. In the fractionated stereotactic radiotherapy
(FSRT), pathologically conﬁrmed radionecrosis was only seen
in series with NTDcum of >105 Gy.9 Fractionated stereotactic
reirradiation was generally performed using a fraction size of
>5 Gy, whereas in radiosurgery (SRS), even single dose fraction
as high as 18 Gy.
The concise overview of existing salvage strategies, their
therapeutic value and associated risk for patients with recur-
rent malignant glioma was recently presented by Niyazi
et al.14 In the current literature there is no such summary
of clinical data on retreatment of children with progressive
CNS tumor.
Recently, Merchant et al. described their experience with
retreatment of children with recurrent ependymoma. The
radiosurgery using median dose of 18 Gy was performed in
6 patients and resulted in signiﬁcant brain stem toxicity. All
children had neuroimaging or pathologic evidence of necro-
sis. Five of them died. For this reason, in subsequent patients,
fractionated reirradiation was performed. This method was
demonstrated as better tolerated and giving excellent local
control: only 3 of 13 children had disease progression. The
conclusion was that high dose single-fraction treatment can
be harmful, especially when such a critical structure as the
brain stem is involved.2
In other reports from Boston Children’s Hospital and Hei-
delberg none of the children with recurrent medulloblastoma
had any evidence of late toxicity or radionecrosis after SRS.
But the median prescription dose was relatively low, 12 Gy and
15 Gy, respectively.4,6
Shaw at al. in the ﬁnal report of RTOG protocol 90–05
demonstrated that the maximum tumor diameter, the perfor-
mance status and the tumor dose were associated with the
risk of neurotoxicity in the reirradiated patients. The actu-
arial risk of radionecrosis was 8% and 11% at 1 and 2 years
following radiosurgery, respectively. The maximum tolerated
doses of single fraction radiosurgery were deﬁned as 24 Gy,
18 Gy and 15 Gy for tumors ≤20 mm,  21–30 mm and 31–40 mm
in maximum diameter.15
Only a few reports have been published on the utility of
intraoperative radiotherapy (IORT) in children, especially on
its toxicity and efﬁciency in recurrent brain tumors. Karapu-
rakal et al. described the preliminary results after IORT with
a photon radiosurgery system in a group of children with
recurrent brain tumors at the ﬁrst dose level of 10 Gy. The
radionecrosis was developed during 6–12 months of follow-
up in three children who were not irradiated earlier but had
received 10 Gy to a depth of 5 mm.  Kalapurkal demonstrated
the safety of IORT to a dose of 10 Gy to 2 mm in children pre-
viously irradiated.16
nd ra
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The promising results were presented by Liu et al. They
chose the hypofractionated regimen of reirradiation. All six
children given three fractions of 8 Gy are alive with no evidence
of disease. In three of them, radionecrosis was suspected
based on MRI  images, but none of them required signiﬁcant
therapy.3
The hypofractionated stereotactic conformal radiotherapy
(SCRT) regimen was used by Saran et al. in retreatment of 14
patients with recurrent or residual medulloblastma/PNET. All
patients received focal radiotherapy (30–40 Gy/6–8 fractions)
using non-coplanar arcs or ﬁxed conformal non-coplanar
ﬁelds. Median OS was 29 months and median PFS was 12
months. At the time of analysis 8 patients died, all due to pro-
gressive disease. In a median time to progression of 12 months,
nine recurrences were observed.5
Bauman at al. reported the retrospective analysis of 34
patients reirradiated for various CNS tumors between 1977
and 1993. Almost two-thirds of the patients were retreated
for the failure located outside the originally treated volume.
The patients were reirradiated with the variety of techniques,
including hypofractionated, conventionally fractionated and
hyperfractionated regimens, for whole or partial brain ﬁelds.
The median cumulative dose was 79.7 Gy (range: 43.2–111 Gy).
The median PFS and OS were 3.3 and 8.3 months, respectively.
The repeated treatment was associated with longer median
survival in medulloblastoma and meningioma patients: 11.5
and 36.1 months, respectively. This may be the consequence
of more  indolent behavior of these histologies. The radiolog-
ical response rate was 58%. The complication rate was 29%
(10/34 pts); including 3 patients with brain necrosis.13
In our group the median overall survival was 17.5 months,
but all children were treated for relatively radiosensitive
tumors. The radiological response rate was also better, with
75% of patients showing stable or improved images during the
ﬁrst evaluation. We  have not observed late toxicity but in none
of the patients the TDcum and BEDcum exceeded 100 Gy and
200 Gy, respectively.
Wara et al. after applying the whole brain reirradiation of up
to 30 Gy in 10 fractions and giving misonidazol to 28 children
with various recurrent brain tumors showed median overall
survival and median time to progression of 13 and 5.5 months,
respectively. Six patients (21%) developed radiation toxicity
and 2 of them died because of this. The whole brain hypofrac-
tionated reirradiation schemes should be avoided as they give
higher risk of late toxicity.12
In Veninga’s series of 42 patients over 16 years, the median
OS and PFS after reirradiation were 10.9 and 8.6 months.
Nearly one-third showed a complete or partial radiological
response. Long term complications were seen in 3 patients,
all of them received the BEDcum of >204 Gy.7
Radionecrosis was reported in only one study with hyper-
fractionated regimen, despite the NTDcum of <90 Gy. This
indicates that the repair of sublethal DNA damage is not com-
pleted in the 6-h interval between two daily fractions.9
The control of craniospinal dissemination remains to be
the main problem in treatment of recurrent brain tumors.
Repeated radiotherapy could have an important role at pre-
venting local relapse. In Saran’s series, the local control rate
was 80% at 1 year. The predominant site of failure was
distant within the CNS.5 Similar results were obtained bydiotherapy 1 7 ( 2 0 1 2 ) 32–37
Milker-Zabel et al. in radiotherapy of recurrent MB. A local
tumor progression was seen in three cases of 20 treated
children. A multifocal intracranial progression was seen in
9 patients, 5 of them developed additional spinal metas-
tases. Thirteen patients died with disseminated cranio-spinal
progression.4 In our analysis, within the ﬁrst year after
repeated radiotherapy, only 2 of 8 children progressed in the
treatment area. At a median follow-up of 16 months, 2 children
died from dissemination within the CNS.
All our patients had salvage chemotherapy preceding
or/and following reirradiation. Salvage chemotherapy regi-
mens may be recommended as the next modality depending
on prior exposure to chemotherapy, anticipated chemosen-
sitivity of the tumor and clinical status of the patient. The
combined radio-chemotherapy is likely to increase some side
effects, especially with substances with strong radiosensitiz-
ing potential.17 However, the use of chemotherapy was not
the signiﬁcant predictor of toxicity. We included only children
reirradiated up to 2009 inclusive to obtain a reliable follow-
up time allowing to assess the risk of late damage, including
radionecrosis. None of our patients developed any late com-
plications. Four children had mild symptoms of radiotherapy
toxicity not requiring medication, the other four had symp-
toms that required steroids in low doses and/or antiemetic
treatment.
6.  Conclusion
The fractionated external beam reirradiation with highly con-
formal three-dimensional planning is certainly an important
modality to be considered in the armamentarium for CNS
tumor recurrence in children. This report demonstrates that
the repeated radiotherapy is not a curative option but could
be a therapeutic choice in the absence of other treatment
possibilities. This method is intended to consolidate salvage
chemotherapy. Reirradiation seems to be effective in inducing
a radiological remission for a relevant period of time with-
out acute and late signiﬁcant sequelae. Patients remained in
a satisfactory functional condition at the time of tumor pro-
gression. The control of craniospinal dissemination remains
to be the main problem. To determine an optimal manage-
ment strategy in children with recurrent brain tumor, it would
be necessary to summarize all single-centre reports of retreat-
ment.
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